報價延遲最少15分鐘:2025/07/17 16:43 EDT
盤後時段
|
||||
|
3.75 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.20/-1.90
|
|
企業價值
666.83M
|
| 資產負債 |
|
每股賬面淨值
4.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.01M
|
|
每股收益
0.15
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971). |
